HUE036224T2 - C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra - Google Patents

C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra

Info

Publication number
HUE036224T2
HUE036224T2 HUE14762343A HUE14762343A HUE036224T2 HU E036224 T2 HUE036224 T2 HU E036224T2 HU E14762343 A HUE14762343 A HU E14762343A HU E14762343 A HUE14762343 A HU E14762343A HU E036224 T2 HUE036224 T2 HU E036224T2
Authority
HU
Hungary
Prior art keywords
prophylaxis
inhibitors
treatment
hereditary angioedema
angioedema
Prior art date
Application number
HUE14762343A
Other languages
English (en)
Hungarian (hu)
Inventor
Cynthia Gallagher
Stephen Ruddy
Mark Manning
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE036224(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of HUE036224T2 publication Critical patent/HUE036224T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HUE14762343A 2013-03-15 2014-03-17 C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra HUE036224T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE036224T2 true HUE036224T2 (hu) 2018-06-28

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17177676A HUE041837T2 (hu) 2013-03-15 2014-03-17 C1-INH készítmények és eljárások C1- észteráz inhibitor elégtelenséggel összefüggõ rendellenességek megelõzésére és kezelésére
HUE14762343A HUE036224T2 (hu) 2013-03-15 2014-03-17 C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE17177676A HUE041837T2 (hu) 2013-03-15 2014-03-17 C1-INH készítmények és eljárások C1- észteráz inhibitor elégtelenséggel összefüggõ rendellenességek megelõzésére és kezelésére

Country Status (30)

Country Link
US (9) US9616111B2 (OSRAM)
EP (3) EP2968434B1 (OSRAM)
JP (9) JP6184581B2 (OSRAM)
KR (4) KR20150135242A (OSRAM)
CN (2) CN105517559A (OSRAM)
AU (3) AU2014232912A1 (OSRAM)
BR (1) BR112015023207A8 (OSRAM)
CA (2) CA3054718A1 (OSRAM)
CY (2) CY1119419T1 (OSRAM)
DE (1) DE202014011208U1 (OSRAM)
DK (2) DK3290046T3 (OSRAM)
EA (1) EA201591278A1 (OSRAM)
ES (2) ES2639833T3 (OSRAM)
GB (1) GB2530921B (OSRAM)
HK (1) HK1250912B (OSRAM)
HR (2) HRP20171269T1 (OSRAM)
HU (2) HUE041837T2 (OSRAM)
IL (2) IL241549B (OSRAM)
LT (2) LT3290046T (OSRAM)
ME (2) ME02865B (OSRAM)
MX (3) MX389449B (OSRAM)
PL (2) PL2968434T3 (OSRAM)
PT (2) PT3290046T (OSRAM)
RS (2) RS58351B1 (OSRAM)
SG (2) SG11201507616VA (OSRAM)
SI (2) SI3290046T1 (OSRAM)
SM (2) SMT201700415T1 (OSRAM)
TR (1) TR201900319T4 (OSRAM)
WO (1) WO2014145519A2 (OSRAM)
ZA (3) ZA201507604B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700415T1 (it) 2013-03-15 2017-11-15 Shire Viropharma Inc Composizioni di c1-inh per l’uso nella prevenzione e nel trattamento dell’angioedema ereditario (hae)
SMT201900042T1 (it) 2013-11-22 2019-02-28 Shire Viropharma Inc Metodi di trattamento del rigetto mediato da anticorpi in pazienti con trapianto d’organo con inibitore della c1-esterasi
WO2016131958A1 (en) * 2015-02-20 2016-08-25 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CN113999875A (zh) * 2015-05-28 2022-02-01 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
BR112018010160A8 (pt) * 2015-11-19 2019-02-26 Shire Human Genetic Therapies inibidor da c1 esterase humana recombinante e usos do mesmo
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
WO2018037046A1 (en) * 2016-08-23 2018-03-01 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
WO2018210944A1 (en) 2017-05-16 2018-11-22 Octapharma Ag C1-esterase inhibitor preparation
CN111818938A (zh) 2018-02-28 2020-10-23 法明知识产权股份有限公司 先兆子痫的治疗和预防
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
CA3104783A1 (en) 2018-06-22 2019-12-26 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
KR20210024050A (ko) 2018-06-22 2021-03-04 가부시키가이샤 준텐 바이오 감염성 면역 관용을 야기하기 위한 조성물
US12397054B2 (en) 2018-06-22 2025-08-26 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
WO2021124793A1 (ja) * 2019-12-16 2021-06-24 ニプロ株式会社 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
US20240342258A1 (en) 2021-07-09 2024-10-17 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
ATE212859T1 (de) 1993-09-01 2002-02-15 Sanquin Bloedvoorziening C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt
WO1997022347A1 (en) 1995-12-18 1997-06-26 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
DE60132169T2 (de) 2000-01-31 2008-12-11 Pharming Intellectual Property Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003300781A1 (en) 2002-09-25 2004-05-04 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
WO2004100982A1 (en) 2003-05-16 2004-11-25 Pharming Intellectual Property B.V. C1 inhibitor with short half-life for transient treatment
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2654440C (en) 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
PT1965831E (pt) * 2005-12-21 2011-10-19 Pharming Intellectual Pty Bv Uso de inibidor c1 para a prevenção da lesão isquémia-reperfusão
PL1965831T3 (pl) 2005-12-21 2011-12-30 Pharming Intellectual Property B V Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
KR101629702B1 (ko) 2007-02-12 2016-06-13 체에스엘 베링 게엠베하 카잘-형 세린 프로테아제 억제제의 치료학적 적용
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
CN104010656B (zh) 2011-09-24 2016-02-24 德国杰特贝林生物制品有限公司 使用免疫球蛋白和c1-抑制剂的联合疗法
KR102022231B1 (ko) * 2011-12-22 2019-09-19 체에스엘 베링 게엠베하 중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도
JP2015512369A (ja) 2012-03-16 2015-04-27 ベルローズ ファーマ，インコーポレーテッド Ｃ１阻害剤のポリマーコンジュゲート
AU2014243704A1 (en) 2013-03-13 2015-09-10 Creatics Llc Methods and compositions for detecting pancreatic cancer
SMT201700415T1 (it) * 2013-03-15 2017-11-15 Shire Viropharma Inc Composizioni di c1-inh per l’uso nella prevenzione e nel trattamento dell’angioedema ereditario (hae)
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック

Also Published As

Publication number Publication date
EP2968434A4 (en) 2016-03-02
LT3290046T (lt) 2019-03-12
ZA201806793B (en) 2020-01-29
GB201519921D0 (en) 2015-12-23
MX2015011281A (es) 2016-03-03
US20200261556A1 (en) 2020-08-20
RS58351B1 (sr) 2019-03-29
AU2018229558A1 (en) 2018-10-04
ME03326B (me) 2019-10-20
NZ751555A (en) 2021-07-30
ZA201507604B (en) 2018-05-30
TR201900319T4 (tr) 2019-02-21
PT2968434T (pt) 2017-09-18
JP2018119000A (ja) 2018-08-02
US20170224788A1 (en) 2017-08-10
CA2904543C (en) 2019-10-08
MX2020004724A (es) 2022-01-18
KR20150135242A (ko) 2015-12-02
US20160015795A1 (en) 2016-01-21
HRP20171269T1 (hr) 2017-11-03
JP6422520B2 (ja) 2018-11-14
US20180085441A1 (en) 2018-03-29
CN111529708A (zh) 2020-08-14
EP2968434B1 (en) 2017-06-28
JP2019073544A (ja) 2019-05-16
KR20210129267A (ko) 2021-10-27
JP6473535B2 (ja) 2019-02-20
LT2968434T (lt) 2017-09-25
CA3054718A1 (en) 2014-09-18
JP6877472B2 (ja) 2021-05-26
KR102430453B1 (ko) 2022-08-05
HUE041837T2 (hu) 2019-05-28
US9616111B2 (en) 2017-04-11
MX373965B (es) 2020-07-13
JP2019073546A (ja) 2019-05-16
US20180153972A1 (en) 2018-06-07
HRP20190270T1 (hr) 2019-04-05
EP3290046B1 (en) 2019-01-02
PL3290046T3 (pl) 2019-05-31
KR102579789B1 (ko) 2023-09-15
SG11201507616VA (en) 2015-10-29
AU2020203183A1 (en) 2020-06-04
SMT201900141T1 (it) 2019-05-10
JP2021088599A (ja) 2021-06-10
EP2968434A2 (en) 2016-01-20
EP3508213A1 (en) 2019-07-10
IL276153B (en) 2022-06-01
BR112015023207A2 (pt) 2017-11-21
KR20220070049A (ko) 2022-05-27
JP2016516073A (ja) 2016-06-02
AU2020203183B2 (en) 2022-06-02
JP6184581B2 (ja) 2017-08-23
BR112015023207A8 (pt) 2018-01-23
US10105423B2 (en) 2018-10-23
MX2021011946A (es) 2021-11-17
US11364288B2 (en) 2022-06-21
DE202014011208U1 (de) 2018-08-23
SI2968434T1 (sl) 2017-11-30
AU2014232912A1 (en) 2015-09-03
CY1119419T1 (el) 2018-03-07
DK2968434T3 (en) 2017-09-11
CY1121653T1 (el) 2020-07-31
WO2014145519A3 (en) 2014-12-31
JP6473534B2 (ja) 2019-02-20
US11534482B2 (en) 2022-12-27
IL276153A (en) 2020-09-30
HK1250912B (en) 2020-01-10
JP2017105847A (ja) 2017-06-15
CA2904543A1 (en) 2014-09-18
GB2530921A (en) 2016-04-06
JP6877470B2 (ja) 2021-05-26
PL2968434T3 (pl) 2018-01-31
JP2018119001A (ja) 2018-08-02
US20190160157A1 (en) 2019-05-30
AU2018229558B2 (en) 2020-03-05
US10080788B2 (en) 2018-09-25
EA201591278A1 (ru) 2016-03-31
SG10201707598QA (en) 2017-10-30
JP2019073545A (ja) 2019-05-16
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
KR20210021146A (ko) 2021-02-24
DK3290046T3 (en) 2019-03-18
ME02865B (me) 2018-04-20
ES2713004T3 (es) 2019-05-17
GB2530921B (en) 2017-09-20
MX389449B (es) 2025-03-20
JP2018119002A (ja) 2018-08-02
JP6877471B2 (ja) 2021-05-26
ZA201706929B (en) 2019-05-29
CN105517559A (zh) 2016-04-20
US20180110844A1 (en) 2018-04-26
EP3290046A1 (en) 2018-03-07
SMT201700415T1 (it) 2017-11-15
JP6473536B2 (ja) 2019-02-20
ES2639833T3 (es) 2017-10-30
IL241549B (en) 2020-08-31
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
PT3290046T (pt) 2019-02-18
WO2014145519A2 (en) 2014-09-18
HK1220403A1 (en) 2017-05-05
SI3290046T1 (sl) 2019-04-30
US20190160158A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
HUE036224T2 (hu) C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra
IL267681A (en) Selective grp94 inhibitors and their uses
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
PL3004110T3 (pl) Pochodne pirazolopirolidynowe i ich zastosowanie w leczeniu choroby
GB201320723D0 (en) Composition and methods of treatment
CL2015002146A1 (es) Composiciones y procedimientos para tratar heridas superficiales
PL3004108T3 (pl) Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
EP3052510A4 (en) Methods and compositions for treating and/or preventing mucositis
HUE054204T2 (hu) Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
HUE067221T2 (hu) IL-1béta inhibitor készítmény és annak alkalmazása
HUE046924T2 (hu) Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
SG10201710538XA (en) Compositions and methods for treating skin
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
ZA201705530B (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
IL311363A (en) Compositions for use in treating cognitive impairment
FI20145861A7 (fi) Multivalentteja yhdisteitä käytettäväksi aivovaurion hoidossa ja estämisessä
EP2974726A4 (en) Agent for the prophylaxis and/or treatment of neoplastic diseases
TH1401007652A (th) อะมิโนไตรอะโซโลไพริดีนสำหรับการใช้ในการรักษาการอักเสบ และองค์ประกอบทางเภสัชกรรมของมัน
ZA201408732B (en) Composition and methods for treating wounds